CTI opens in Singapore with further expansion in Asia planned

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/KCHL)
(Image: Getty/KCHL)

Related tags: Cti clinical trial, Contract research organization, Clinical trial

CTI Clinical Trial and Consulting Services (CTI) has opened a new office in Singapore – a location that will enable the CRO to attract and retain talent as it continues expansion in Asia.

The offices will operate as a wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Singapore Pte. Ltd.

The contract research organization (CRO) has opened more than a dozen offices over the past few years, including new offices in Taipei, Taiwan and Tokyo, Japan in June of 2017.

Pat Earley, vice president, International, CTI, told us the company chose to expand into Singapore because “it is a critically important location for cutting-edge, innovative research including cell and gene therapy which CTI specializes in​.”

The leading academic centers and regulatory authorities have displayed a willingness to develop very open partnerships with pharmaceutical companies, biotechnology companies, and CROs, making Singapore a very desirable county for us to do business in​,” he said.

The specific office location was chosen due to its proximity to the Singapore business district and access to medical centers and transportation.

Its central location will help us attract and retain a qualified workforce as we expand in the area​,” added Earley.

According to the company, additional expansions are planned in Asia over the next 12 to 18 months.

The expansion news come on the heels of CTI’s acquisition of Eurotrials in December ​ – a deal that created “one of the 20 largest CROs in the world​,” Timothy J. Schroeder, CTI founder and CEO said at the time.

Related news

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars